The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Although data from The New England Journal of Medicine published in November 2024 confirmed that inebilizumab (Uplizna, Amgen) significantly reduced the risk for IgG4-related disease (IgG4-RD ...

High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The ...

Turning to rare disease. Our four key growth drivers: TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS, are all early in their life cycles and well positioned for long-term growth. UPLIZNA is a ...

And they said Uplizna, which is in development for a muscle weakening disease called myasthenia gravis, didn’t appear as effective as already approved therapies for the condition.

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon Therapeutics.

Changing the game with evidence and efficacy Speaking with Kristina Patterson of Horizon Therapeutics, pharmaphorum discussed the recent data presented on UPLIZNA as a treatment for NMOSD at the ...

Amgen announced that the US Food and Drug Administration (FDA) has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.